Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer
Matthew P Goetz, Miguel Martín, Eriko Tokunaga, In Hae Park, Jens Huober, Masakazu Toi, Clemens Stoffregen, Sarah Shekarriz, Valerie Andre, M Corona Gainford, Gregory L Price & Stephen Johnston
The addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) was not associated with a clinically meaningful detriment in patient-reported global health-related quality of life, functioning, and most symptoms in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Prior studies have also demonstrated clinical efficacy of abemaciclib plus NSAI compared with NSAI alone, including improved progression-free survival and objective response rate. These results also complement previously reported toxicity data, as measured by investigator-assessed adverse events. Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC.
|citation||Goetz M P, Martín M, Tokunaga E, Park I H, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford M C, Price G L, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020; 25:e1346-e1354.|
|type||journal paper/review (English)|
|date of publishing||24-06-2020|
|journal title||Oncologist (25/9)|